• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Endo reports Q2 beat on rev, earnings

Endo reports Q2 beat on rev, earnings

August 10, 2015 By Fink Densford

Endo reports Q2 beat on rev, earningsEndo Health Solutions (NSDQ:ENDP) reported 2nd quarter earnings today that beat expectations for revenue and earnings per share by a fair margin while continuing its acquisition plans for Par Pharmaceuticals.

Endo International reported losses of $250.5 million, or $1.35 per share, on sales of $735.2 million for the 3 months ended June 30.

Adjusted to exclude 1-time items, earnings per share were $1.20, beating analyst expectations by 18¢. Adjusted profits were up a healthy 29.5% from last year as well, and EPS growth clocked in at 13.2%

The company also beat revenue expectations by nearly $8 million, though shares have been sluggish to respond, rising a meager 0.39% as of mid-day trading today.

“Our diversified business delivered strong financial results for the quarter and demonstrated the value that we expect to create through the continued execution of our strategy. We are close to completing the integration planning for our acquisition of Par and we remain excited by the strategic expansion of our product portfolio, R&D pipeline and long-term growth profile that the Par assets and Par talent joining Endo are expected to help provide. Looking ahead to the second half of 2015 and beyond, we are focused on accelerating growth in our current U.S. branded pharmaceuticals portfolio and continue to expect that our strategic M&A and pipeline development efforts will yield future growth drivers,” Endo CEO Rajiv De Silva said in a prepared statement.

Endo reaffirmed and slightly adjusted its guidance for the rest of the year, expecting revenue between $2.9 and $3 billion and EPS between $1.42 and $1.62, adjusted down from the range of $1.70 to $1.90.

Last week, Endo announced it is selling off certain assets from its South Africa-based Litha Healthcare subsidiary. The assets, a portfolio of device, vaccine and non-core products, are being acquired by a consortium comprised of Westrate Trade, Invest Proprietary Limited and Immunotek Limited, according to the company.

Also announced last week, Boston Scientific (NYSE:BSX) closed its $1.6 billion acquisition of Endo’s American Medical Systems urology portfolio, including its men’s health and prostate health businesses.

Filed Under: Business/Financial News, MassDevice Earnings Roundup Tagged With: Endo Health

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy